News | November 10, 2024
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
Q2 FY25 Total Income was at Rs. 85.4 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated
